2023-08-25 20:30:00
The treatment will be available in health establishments and pharmacies from mid-September, the Ministry of Health announced.
By IM with AFP
© PFG/SIPA / SIPA
Published on
Subscriber-only audio playback
Le Beyfortus, a preventive treatment for bronchiolitis from Sanofi and AstraZeneca intended for newborns, will be available “from mid-September” in health establishments and, on order, in pharmacies, the Ministry of Health said in a document sent to health professionals. This monoclonal antibody (nirsevimab) is one of the options once morest respiratory syncytial virus, the main cause of bronchiolitis, in infants during their first season of exposure to RSV.
“Available from mid-September in health establishments and on order in community pharmacies, nirsevimab may be prescribed to all infants born from February 6, 2023 in mainland France”, it is specified in the document (DGS Urgent) from the Ministry. For the overseas territories, the “specificities […] are under investigation”.
READ ALSOShortage of drugs: the severe report of the senators
The single injection, in the muscle, can be done in some cases at birth. For infants born from September 15, it is recommended that they be “immunized before leaving the maternity ward”, the ministry told caregivers. The antibody can also be administered in town, in general practice, pediatrics, health centers, etc. In this case, it will be necessary “a prescription by the doctor who follows the child”, according to the document. “Parents will then go to the community pharmacy to order and then collect the medicine which will be made available by the State, without invoicing the families”.
2-3% of infants hospitalized for severe bronchiolitis
In France, it is estimated that bronchiolitis affects nearly 30% of infants under two years of age each winter, i.e. approximately 480,000 cases per year. And 2-3% of infants under the age of one are hospitalized for severe bronchiolitis.
The bronchiolitis epidemic in France last winter reached an unprecedented level for more than ten years: it required more than 26,000 hospitalizations following a visit to the emergency room in children under two years old, according to numbers from the emergency services.
READ ALSOEnd clap for the Covid-19 pandemic?
Alongside an information campaign on bronchiolitis aimed at parents, the deployment of a preventive treatment once morest bronchiolitis will constitute “one of the major challenges of the new school year”, declared in early August the Minister of Health, Aurélien Rousseau, the day following the green light from the High Authority for Health for reimbursement.
Beyfortus provides “a partial response to the medical need” because there is not yet any data to “support a possible impact” on the duration of hospitalization, transfer to intensive care or intensive care, mortality, according to the HAS.
1693203694
#preventive #treatment #bronchiolitis #babies
